Super interesting N=1 case study from the PSMA experts in Germany. Like me, you've probably never heard of transketolase or why you would even want to inhibit it. Turns out transketolase is a thiamine-dependent enzyme that serves as the rate-limiting enzyme in the non-oxidative branch of the Pentose Phosphate Pathway. - if that helps you at all.
This particular case is one of a patient with metastatic disease who rapidly progressed in spite of aggressive treatment. He was PSMA-avid on scans, so serially treated with various PSMA radioligands. Late series inclusion of the thiamine antagonist benfo-oxythiamine (B-OT) improved his response and extended his life by an additional 12 months. The docs believe this n=1 adds support to their theory that adding B-OT to PSMA therapy can overcome radiation resistance in PCa.
* * *
The NIH National Library of Medicine's National Center for Biotechnology Information currently lists 179 related citations on PubMed for the transketolase gene, TKT . The most abundant location of the TKT gene is in bone - and by a very large margin, with ranges for fat less than 1/2 and prostate not even 1/4 the amount in bone. Here is a link to the NIH site:
* * *
Full Case Report is here:
Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer—A case report, CASE REPORT article
Front. Med., 08 October 2024, Sec. Nuclear Medicine, Volume 11 - 2024.
frontiersin.org/journals/me...
* * *
As our loyal friend npfisherman is fond of saying . . . "The Science is Coming".
Y'all Stay S&W, Ciao - Capt'n cujoe